Quick Facts: Therapeutic Domains

• Emergency supportive care for severe allergic reactions.
• Used for anaphylaxis caused by stings, foods, medicines, or other allergens.
• Intended for individuals deemed at risk for life-threatening allergic episodes.

ЭПИДЖЕКТ (Epinephrine auto-injector) is indicated for the emergency supportive treatment of severe allergic reactions, including anaphylaxis. This medication is intended for immediate administration in individuals who are considered to be at an increased risk for serious allergic episodes, or who have a history of such reactions. It may be used to address reactions triggered by allergens such as insect stings, biting insects, certain foods, or medications.

The medication is designed to provide immediate care to help manage the signs and symptoms of anaphylaxis. It is not intended as a substitute for seeking immediate medical attention from a healthcare provider. After using the auto-injector, a patient should promptly obtain additional medical care. Epinephrine is considered the primary option for addressing these life-threatening allergic situations.

For a detailed overview of the approved uses and safety information, patients should consult the authorized product labeling.

Who Can and Cannot Use ЭПИДЖЕКТ (Epinephrine Auto-Injector)

This section outlines population eligibility based strictly on official regulatory labeling for the emergency use of epinephrine auto-injectors.

Contraindications and Restrictions

Official prescribing information confirms that no absolute contraindications exist for using ЭПИДЖЕКТ in the context of an acute, life-threatening allergic reaction (anaphylaxis). The risk of withholding the life-saving medication is considered to outweigh any potential risk from pre-existing conditions.

Category	Official Regulatory Status
Absolute Contraindications	None listed for emergency use.
Use Not Established	Children weighing less than 15 kg (33 pounds).

---

Age and Condition Considerations

Eligibility is defined by body weight to ensure the correct dose is delivered:

• 0.3 mg dose: Approved for patients weighing 30 kg or more.
• 0.15 mg dose: Approved for patients weighing 15 kg to 30 kg.

Use requires caution in specific populations, as they may be at a greater risk of adverse reactions. These conditions include heart disease, hypertension, hyperthyroidism, and diabetes. However, these conditions do not prohibit emergency administration. Official labeling states that the benefits of use during pregnancy and lactation outweigh the risks in an anaphylactic crisis.

Interactions with other medicines and products

Official government drug labels document several pharmacodynamic and metabolic interactions for epinephrine, the active ingredient in ЭПИДЖЕКТ. These interactions primarily affect cardiovascular function, as the medication is an adrenergic agonist.

Interaction Type	Interacting Categories (Examples)	Official Regulatory Outcome
Potentiation	Tricyclic Antidepressants (TCAs), MAO Inhibitors	Risk of severe, prolonged hypertension is documented.
Antagonism	Alpha-Adrenergic Blocking Drugs (alpha-blockers)	Counteract or reverse the pressor effects of epinephrine.
Arrhythmia Risk	Beta-Blockers, Halogenated Anesthetics, Cardiac Glycosides	Increase the potential for serious cardiac arrhythmias.
Metabolic Effect	COMT Inhibitors, Thyroid Hormones	Potentiate the pressor effects by inhibiting epinephrine clearance.

Tricyclic Antidepressants and Monoamine Oxidase Inhibitors (MAOIs), in particular, are officially noted to increase the risk of severe, prolonged hypertension when co-administered. Beta-Blockers are documented to antagonize the cardiostimulating and bronchodilating effects. Furthermore, epinephrine is noted to cause a transient increase in blood glucose levels, which is a population-specific interaction consideration for diabetic patients using anti-diabetic agents. The regulatory profile emphasizes heightened observation with these combinations.

How ЭПИДЖЕКТ Works

ЭПИДЖЕКТ is a nitrogen-containing bisphosphonate that acts as a structural analog of pyrophosphate. It achieves its specific biological activity by binding directly to the hydroxyapatite mineral surface of the bone matrix, where it accumulates selectively in areas of active bone remodeling. This targeted binding is the prerequisite for cellular uptake into osteoclasts.

The core molecular action occurs inside the osteoclast following internalization, where ЭПИДЖЕКТ inhibits the enzyme farnesyl diphosphate synthase (FPPS). Inhibition of FPPS disrupts the mevalonate pathway, preventing the prenylation of small GTPase proteins essential for the cell's function and cytoskeletal integrity.

This cascade, beginning with specific mineral binding and ending with FPPS inhibition, causes the osteoclast to lose its resorptive capacity, leading to a cessation of bone tissue degradation. The resulting physiological effect is a modification of the balance of bone remodeling through the selective decrease of bone resorption.

ЭПИДЖЕКТ (Valproate Sodium Injection), or EPIJECT® I.V., is an intravenous (IV) formulation of valproate that is administered by or under the direct supervision of a healthcare professional. It is typically used for patients with epilepsy, acute mania, or migraine where the oral form of valproate is temporarily not feasible, such as when a patient is nil per os (NPO) or requires a quick attainment of a therapeutic concentration.

Administration

ЭПИДЖЕКТ is administered as a 60-minute intravenous infusion. A healthcare provider will slowly inject the medicine into a vein. The specific dosage and frequency are determined by the treating physician based on the patient's condition, weight, and concurrent medication use. The goal is to achieve an equivalent systemic exposure to the oral valproate products. It is important for the patient to be closely monitored by a physician while receiving this medication, as blood tests may be required to check the drug's plasma concentration and monitor for potential adverse effects, especially liver function.

Storage and Handling

This medication must be handled by trained personnel in a medical facility. The unmixed injection vials should be stored at controlled room temperature, away from excessive heat or moisture, as specified in the product labeling. Medications must remain in their original containers to ensure integrity. Once the vial is accessed or diluted for infusion, the solution should be used promptly. Any unused portion must be disposed of according to facility protocol and local regulations, following guidelines for safe medication disposal.

Research evidence / Overview of studies for ЭПИДЖЕКТ

---

Conditions Characterized by Fluctuating or Episodic Manifestations

EPIDJECT was studied for research exploring conditions characterized by fluctuating or episodic manifestations. These studies explored how symptoms change over time and were applied in research contexts involving fluctuating or unstable symptoms. The evidence derived from these settings focuses on outcomes reflecting daily functioning or activity level, or those describing episodic or acute changes. The research describes patterns observed during periods of increased symptom activity, and studies monitored responses over defined time intervals.

Data show patterns related to changes measured during the study period. Data show patterns related to outcomes capturing phases of heightened symptom activity. Studies report how symptoms evolved in the observed populations, and findings help contextualize how patients reported their experience in conditions presenting with cycles of stability and flare-ups.

However, the evidence is limited, and data are still emerging. The research is ongoing, and long-term effects are not fully established. Subgroup findings are uncertain, and comparative evidence is lacking. Research provides context but not individual predictions, and studies help show what has been observed so far, which reflects the specific conditions under which they were conducted.

---

Evidence for Outcomes Related to Physical Discomfort

EPIDJECT was evaluated in studies assessing outcomes related to patient-reported perceived discomfort. These studies were relevant in trials assessing short-term or episodic symptom patterns and focused on outcomes related to systemic or functional imbalance. Research examined temporary physiological imbalance in observational settings evaluating daily-life functioning.

Research has explored whether patterns are related to outcomes linked to inflammatory or irritative states. Research highlights changes measured during the study period, and research provides insight into short-term changes. Certain changes in outcomes related to physical discomfort were observed in these trials. Findings were mixed in some populations, and certainty remains low in some of the analyses.

A key research limitation is that results apply only to the populations studied. Sample sizes were modest in a number of reports, and follow-up durations were limited. Data for certain groups remain insufficient. The research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes. The evidence highlights what is known — and what is still uncertain.

Common questions about ЭПИДЖЕКТ (FAQ)

Q: What is ЭПИДЖЕКТ and how does it work?

ЭПИДЖЕКТ is a pre-filled pen containing epinephrine (also known as adrenaline). It is a medication used for the emergency treatment of severe allergic reactions (anaphylaxis). Epinephrine is a naturally occurring chemical that works by rapidly reversing the life-threatening effects of anaphylaxis. It acts on the body's alpha and beta receptors to constrict blood vessels (increasing blood pressure), relax the muscles in the lungs (improving breathing), and reduce swelling.

Q: What is ЭПИДЖЕКТ used to treat?

ЭПИДЖЕКТ is used to treat anaphylaxis (severe, life-threatening allergic reactions). These reactions can be caused by exposure to various triggers, including:

• Insect stings or bites (like bees, wasps, or hornets)
• Foods (like peanuts, tree nuts, milk, eggs, or shellfish)
• Medicines or drugs
• Latex or other substances

Q: What are the side effects of ЭПИДЖЕКТ?

Since ЭПИДЖЕКТ is used in life-threatening emergencies, potential side effects are usually not the primary concern. Common, but generally short-lived, side effects related to epinephrine can include:

• Fast, pounding, or irregular heartbeat (palpitations)
• Anxiety or restlessness
• Dizziness or lightheadedness
• Tremor or shaking
• Sweating
• Headache
• Nausea or vomiting

If you experience severe or persistent side effects, or if the anaphylactic reaction does not improve, seek immediate medical attention.

Q: How should I store ЭПИДЖЕКТ?

ЭПИДЖЕКТ auto-injectors should be stored at room temperature, typically between 59 F and 77 F (15 C and 25 C). It is crucial to:

• Keep it in its outer carton to protect it from light.
• Avoid exposing it to extreme temperatures (do not refrigerate or freeze, and do not store in a hot car).
• Check the solution through the viewing window periodically. If the solution appears discolored (pink or brown) or cloudy, or if it contains solid particles, it should be replaced immediately, even if it has not reached the expiration date.
• Always check the expiration date and replace the pen before it expires.

Q: What is the proper way to use ЭПИДЖЕКТ?

ЭПИДЖЕКТ is designed for immediate, self-administration or administration by a caregiver at the first signs of anaphylaxis. The specific steps may vary slightly depending on the device version, so it is essential to be trained by a healthcare professional and read the instructions provided with your specific device.

In general, the proper technique involves:

1. Grasp the device in your dominant hand.
2. Remove the safety cap(s) as instructed.
3. Firmly press and hold the tip against the middle of the outer thigh (through clothing is acceptable).
4. Hold in place for the recommended time (usually several seconds) to ensure the full dose is delivered.
5. Seek immediate emergency medical help (call a local emergency number) even if symptoms improve, as a second reaction may occur.

The official regulatory requirements for storing and disposing of ЭПИДЖЕКТ are critical for maintaining the product's stability and safety.

Storage Conditions
Temperature	Controlled room temperature, generally 20 C to 25 C, with permitted excursions between 15 C and 30 C.
Restrictions	Do not refrigerate and do not freeze. Must not be stored in a vehicle glove box.
Protection	Must be stored in its original carrier tube or carton and protected from light.
Integrity Check	The solution must be clear and colorless; replace the auto-injector if it is discolored or contains precipitate.

Disposal Instructions
Used Device	The device is single-use only and must be disposed of immediately after use.
Sharps Waste	Used auto-injectors are classified as Sharps and must be taken to a healthcare professional, hospital, or pharmacy for proper medical sharps disposal.
Child Safety	Must be kept out of the sight and reach of children.